Skip to main content

Market Overview

Analyst Says Teva Is 'Plagued With Problems,' Downgrades On Challenging Outlook

Analyst Says Teva Is 'Plagued With Problems,' Downgrades On Challenging Outlook

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) have lost 30 percent in the last six months and are currently trading close to 10-year lows. However, a turnaround in shares is unlikely until there are “signs of potential growth or a clearer strategy from the new management team,” Argus’s John Eade wrote in a report.

Eade downgraded the rating on Teva from Buy to Hold, citing a “challenging outlook.” He added that there were other segments of the healthcare industry that offered “better growth prospects at reasonable valuations.”

Challenging Outlook

Eade commented that the company was “plagued with problems,” while citing the following:

Related Link: Risks For Teva Remain As CEO Search Continues

Teva’s shares have been under pressure partly due to headwinds in the generics pharmaceutical industry, the analyst noted. He added, “Pharmaceutical distributors in our coverage universe forecast generics price erosion of 7–10 percent in 2017, which will shrink margins for both distributors and manufacturers.”

Although Teva could grow through M&A, there would be antitrust hurdles, Eade mentioned. Moreover, following the acquisition of the Actavis generics business, “there are few (if any) attractive large targets.”

Latest Ratings for TEVA

Nov 2020OppenheimerInitiates Coverage OnPerform
Nov 2020BMO CapitalMaintainsMarket Perform
Aug 2020BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Downgrades Health Care Analyst Ratings Movers General Best of Benzinga

Latest Ratings

SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at